A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers

Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The pancreas is a gland behind the stomach that produces a digestive fluid that is emptied into the intestines through tube shaped ducts. Pancreatic cancer often starts in these ducts. The goal of this study is to evaluate the safety and efficacy of telisotuzumab adizutecan in combination with gemcitabine and nab-paclitaxel in adult participants with pancreatobiliary cancers. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of pancreatobiliary cancers. In Su

Trial Details

NCT ID
NCT07769502
Phase
PHASE2
Sponsor
AbbVie
Status
RECRUITING
Cancer Type
Pancreatic Ductal Adenocarcinoma Pancreatic Cancer
Interventions
  • Telisotuzumab Adizutecan
  • Gemcitabine
  • Nab-Paclitaxel
Locations (sample)
  • Ramat Gan, Tel Aviv, Israel|32.08227,34.81065
  • Jerusalem, Israel|31.76904,35.21633
  • Yokohama, Kanagawa, Japan|35.43333,139.65
  • Osaka, Osaka, Japan|34.69379,135.50107
  • Chuo-Ku, Tokyo, Japan

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) Performance status (PS) of 0 or 1.
  • Resolution of any acute clinically significant treatment-related toxicity from prior therapy to Grade \<= 1 prior to study entry (except for alopec…
  • Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at baseline. Lesions situated in a previously irradiated area are…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →